COMT

Catechol-O-methyltransferase (COMT) is an enzyme that breaks down catecholamines — a family of signalling molecules that includes dopamine, norepinephrine, and epinephrine. It does this by transferring a methyl group onto the catecholamine, rendering it inactive and ready for clearance.

COMT is found throughout the body but is especially consequential in the prefrontal cortex, where it serves as the primary route by which dopamine is removed after release. This makes it a significant regulator of higher cognitive functions: working memory, attention, and executive control all depend on having dopamine levels in the prefrontal cortex within a functional range.

The gene encoding COMT harbours a well-studied variant — commonly called Val158Met — that produces either a high-activity (Val) or low-activity (Met) form of the enzyme. People inherit one copy from each parent, giving three possible combinations. This variation makes COMT one of the better-documented examples of how a single common gene variant can measurably shift brain function and, in turn, drug response.

How it works · its role

COMT catalyses methylation: it transfers a methyl group from the cofactor S-adenosyl-L-methionine onto its substrate, inactivating the catecholamine. In most brain regions, dopamine is cleared mainly by the DAT (DAT); the prefrontal cortex, however, has relatively few DAT molecules, so COMT carries an outsized share of the workload there.

The Val158Met substitution changes the enzyme's thermal stability. The Val variant is more active at body temperature, breaking down dopamine faster and holding prefrontal levels lower. The Met variant is less active, allowing dopamine to persist longer in the synapse.

Because the prefrontal cortex operates best within a moderate dopamine range — too little or too much both impair function — the balance point shifts with genotype. Met homozygotes tend toward higher baseline prefrontal dopamine; Val homozygotes toward lower. Neither extreme is straightforwardly advantageous: each trades off differently under stress or cognitive load.

Relevance to substances & effects

Any substance that raises catecholamine levels interacts with COMT, because COMT is part of the pathway that eventually clears them. Stimulants such as amphetamines flood the synapse with dopamine and norepinephrine; COMT, alongside other clearance mechanisms, then degrades the excess.

MAOIs block monoamine oxidase, the other major catecholamine-degrading enzyme, shifting more of the metabolic burden onto COMT. In the presence of an MAOI, COMT inhibitors — used clinically to prolong the effect of levodopa in Parkinson's disease — can push catecholamine levels substantially higher.

Genotype shapes how people respond to dopaminergic drugs. Evidence suggests that individuals with Val/Val genotype, who have lower baseline prefrontal dopamine, may show a larger cognitive benefit from low-dose stimulants; Met/Met individuals, already near the top of the inverted-U curve, may experience less benefit or even impairment at the same dose. Similar genotype-dependent variation has been observed in responses to cannabis and to pain.

COMT is also relevant to the pharmacology of catechol-containing compounds: catechol-structured molecules are direct COMT substrates, meaning their duration and potency are partly a function of how quickly COMT metabolises them.